AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30716132 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbow flexion force
Number of subjects: 48
Study 30716132 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical quality of life
Number of subjects: 48
Study 30716132 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental quality of life
Number of subjects: 48
Study 30716132 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease duration
Number of subjects: 48
Study 30716769 — intervention group
Group type: EXPERIMENTAL
Intervention: Compounded pain creams for neuropathic pain (ketamine, gabapentin, clonidine, and lidocaine)
Number of subjects: 399
Study 30716769 — intervention group
Group type: EXPERIMENTAL
Intervention: Compounded pain creams for nociceptive pain (ketoprofen, baclofen, cyclobenzaprine, and lidocaine)
Number of subjects: 399
Study 30716769 — intervention group
Group type: EXPERIMENTAL
Intervention: Compounded pain creams for mixed pain (ketamine, gabapentin, diclofenac, baclofen, cyclobenzaprine, and lidocaine)
Number of subjects: 399
Study 30716769 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (compounded pain creams)
Number of subjects: 399
Study 30716769 — intervention group
Group type: COMPARATOR
Intervention: Placebo creams
Number of subjects: 399
Study 30717046 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored Anesthesia Care (MAC)
Number of subjects: 40
Study 30717046 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 40
Study 30717046 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 30717050 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable ultrasound device
Number of subjects: 15
Study 30717616 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 33024
Study 30717697 — intervention group
Group type: EXPERIMENTAL
Intervention: First stroke
Number of subjects: 0
Study 30717697 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent strokes
Number of subjects: 0
Study 30717697 — intervention group
Group type: EXPERIMENTAL
Intervention: All strokes
Number of subjects: 0
Study 30717697 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of stroke
Number of subjects: 0
Study 30717697 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident cases of stroke
Number of subjects: 0
Study 30717697 — intervention group
Group type: COMPARATOR
Intervention: Age group 90 years and above
Number of subjects: 0
Study 30717745 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine Electronic Monitoring of Health-Related Quality of Life (REMOQOL) using electronic patient-reported outcomes (e-PRO)
Number of subjects: 56
Study 30717745 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' satisfaction with REMOQOL
Number of subjects: 56
Study 30717802 — intervention group
Group type: EXPERIMENTAL
Intervention: MRX34 (miR-34a mimics)
Number of subjects: 0
Study 30717802 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-34a
Number of subjects: 0
Study 30718102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg daily)
Number of subjects: 43
Study 30718242 — intervention group
Group type: EXPERIMENTAL
Intervention: Malglycemia (hypoglycemia, hyperglycemia, and/or glycemic variability)
Number of subjects: 344
Study 30718242 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 0 to 100 mean glucose of 100 to 124 mg/dL
Number of subjects: 344
Study 30718519 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid/long-acting β agonists prescribed as per usual clinical practice
Number of subjects: 4491
Study 30718519 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (observational study)
Number of subjects: 4491
Study 30718541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) treatment
Number of subjects: 0
Study 30718541 — intervention group
Group type: EXPERIMENTAL
Intervention: Orexin 1 (OX) related intervention
Number of subjects: 0
Study 30718808 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally expanded TILs (Young TILs) established from patients with OC.
Number of subjects: 33
Study 30718808 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive cell transfer (ACT) with TILs.
Number of subjects: 33
Study 30718945 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Reported Experience Measures (PREMs)
Number of subjects: 0
Study 30718945 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Adaptive Testing (CAT)
Number of subjects: 0
Study 30719273 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithyroid drugs
Number of subjects: 0
Study 30719425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilixadencel (10 × 10^6 cells)
Number of subjects: 17
Study 30719425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilixadencel combined with Sorafenib
Number of subjects: 17
Study 30719976 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb (bioresorbable scaffold)
Number of subjects: 388
Study 30719976 — intervention group
Group type: COMPARATOR
Intervention: EES (everolimus-eluting metallic stents)
Number of subjects: 388
Study 30720439 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging (SMS) reminders; 3 reminders to visit primary care physician.
Number of subjects: 470
Study 30720439 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group); alert to physician regarding positive FOBT result.
Number of subjects: 470
Study 30720439 — intervention group
Group type: COMPARATOR
Intervention: Text messaging (SMS) reminders vs. control (routine care).
Number of subjects: 470
Study 30720689 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical-related donor HSCT performed 2 months after liver transplantation
Number of subjects: 1
Study 30720689 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-lobe orthotopic liver transplant
Number of subjects: 1
Study 30720781 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Physical Activity (HIPA) group
Number of subjects: 0
Study 30720781 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundamental Movement Skill (FMS) group
Number of subjects: 0
Study 30720781 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Signposting (PASS) group
Number of subjects: 0
Study 30720781 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30720784 — intervention group
Group type: EXPERIMENTAL
Intervention: Park prescription intervention including an information pack, access to a weekly group exercise program in parks, and telephone counselling.
Number of subjects: 0
Study 30720784 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 0
Study 30721110 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab and Trastuzumab (PT)
Number of subjects: 88
Study 30721341 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg every 2 weeks until confirmed progression, unacceptable toxicity, or withdrawal
Number of subjects: 88
Study 30721341 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg
Number of subjects: 88
Study 30721531 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal holding during therapeutic hypothermia
Number of subjects: 10
Study 30721554 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin (hscTnT) ≤ 5 ng/L
Number of subjects: 3392
Study 30721554 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin (hscTnT) > 50 ng/L
Number of subjects: 3392
Study 30721554 — intervention group
Group type: EXPERIMENTAL
Intervention: Natriuretic peptide (NT-proBNP) ≤ 125 ng/L
Number of subjects: 3392
Study 30721554 — intervention group
Group type: EXPERIMENTAL
Intervention: Natriuretic peptide (NT-proBNP) > 2,000 ng/L
Number of subjects: 3392
Study 30721721 — intervention group
Group type: COMPARATOR
Intervention: 40 Gy in 5 fractions
Number of subjects: 26
Study 30721721 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 Gy in 5 fractions
Number of subjects: 26
Study 30721721 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Gy in 5 fractions
Number of subjects: 26
Study 30721917 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of acidified milk (800 g) containing 38.8 g lactose
Number of subjects: 14
Study 30721972 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal nutritional interventions
Number of subjects: 0
Study 30722097 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg azithromycin thrice weekly for 12 weeks
Number of subjects: 30
Study 30722718 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral endovascular device intervention
Number of subjects: 1204
Study 30722822 — intervention group
Group type: EXPERIMENTAL
Intervention: Clostridium histolyticum collagenase
Number of subjects: 159
Study 30722827 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass or sleeve gastrectomy
Number of subjects: 40
Study 30722827 — intervention group
Group type: COMPARATOR
Intervention: High-risk category based on psychosocial assessment
Number of subjects: 40
Study 30723059 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-adherent care
Number of subjects: 305
Study 30723059 — intervention group
Group type: EXPERIMENTAL
Intervention: Documenting menopausal status
Number of subjects: 305
Study 30723059 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordering diagnostic studies and referrals for postmenopausal women
Number of subjects: 305
Study 30723059 — intervention group
Group type: EXPERIMENTAL
Intervention: Documenting bleeding patterns
Number of subjects: 305
Study 30723059 — intervention group
Group type: EXPERIMENTAL
Intervention: Documenting whether there was active bleeding
Number of subjects: 305
Study 30723059 — intervention group
Group type: EXPERIMENTAL
Intervention: Performing thyroid testing
Number of subjects: 305
Study 30723059 — intervention group
Group type: EXPERIMENTAL
Intervention: Performing a pelvic examination
Number of subjects: 305
Study 30723059 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordering diagnostic studies and referrals in younger women with increased endometrial cancer risk
Number of subjects: 305
Study 30723059 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessing for pregnancy
Number of subjects: 305
Study 30723059 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessing for cervical motion, uterine, or adnexal tenderness in patients with intrauterine devices
Number of subjects: 305
Study 30723059 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessing for elevated endometrial cancer risk
Number of subjects: 305
Study 30723059 — intervention group
Group type: COMPARATOR
Intervention: Overall guideline adherence by VA Designated Women's Health Providers
Number of subjects: 305
Study 30723059 — intervention group
Group type: COMPARATOR
Intervention: Overall guideline adherence by provider volume of encounters with women veterans
Number of subjects: 305
Study 30723079 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of sCD163 at the time of interim PET (PET2)
Number of subjects: 559
Study 30723079 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of TARC, MDC, and IL-10 after therapy
Number of subjects: 559
Study 30723079 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of TARC and IL-10 after therapy
Number of subjects: 559
Study 30723079 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttherapy levels of TARC and IL-10 in PET2-negative patients
Number of subjects: 559
Study 30723407 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-derived microparticles from obese individuals
Number of subjects: 0
Study 30723455 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidirectional rotations
Number of subjects: 0
Study 30723727 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational study data collection including clinical assessments, spirometry, biospecimens, patient-reported outcomes (PROs), and healthcare utilization (HCU) collected yearly and 3-monthly.
Number of subjects: 12000
Study 30723839 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph Node Yield (LNY)
Number of subjects: 0
Study 30723839 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph Node Ratio (LNR)
Number of subjects: 0
Study 30723839 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Survival (OS)
Number of subjects: 0
Study 30723839 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease Specific Survival (DSS)
Number of subjects: 0
Study 30723839 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression Free Survival Hazard Ratios (HR)
Number of subjects: 0
Study 30723894 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 1000 mg
Number of subjects: 51
Study 30723894 — intervention group
Group type: COMPARATOR
Intervention: Ofatumumab 500 mg
Number of subjects: 51
Study 30724096 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg
Number of subjects: 0
Study 30724096 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg
Number of subjects: 0
Study 30724096 — intervention group
Group type: COMPARATOR
Intervention: Elagolix
Number of subjects: 0
Study 30724096 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate
Number of subjects: 0
Study 30724101 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified texture food use
Number of subjects: 0
Study 30724333 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP adherence (defined as CPAP use 4 hours or more per night over 1 year)
Number of subjects: 54
Study 30724333 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP adherence (MCI +CPAP)
Number of subjects: 54
Study 30724333 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI +CPAP
Number of subjects: 54
Study 30724333 — intervention group
Group type: COMPARATOR
Intervention: MCI -CPAP (control group)
Number of subjects: 54
Study 30724422 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic treatment
Number of subjects: 94
Study 30724422 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment
Number of subjects: 94
Study 30724423 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib capsules (100 mg q.d. to 600 mg b.i.d.)
Number of subjects: 44
Study 30724423 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib tablets (200 mg b.i.d. and 400 mg b.i.d.)
Number of subjects: 44
Study 30724423 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib (both formulations)
Number of subjects: 44
Study 30724735 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital educational program (4-week online program with written information, videos, and social networking features)
Number of subjects: 25
Study 30724735 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital educational program
Number of subjects: 25
Study 30724734 — intervention group
Group type: EXPERIMENTAL
Intervention: EA-230 (90 mg/kg/hour)
Number of subjects: 180
Study 30724734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 30724759 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily oral extended-release bupropion (BRP, Welbutrin XL, 450 mg/day)
Number of subjects: 49
Study 30724759 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone video dosing
Number of subjects: 49
Study 30725293 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate (TDF) therapy for 144 weeks
Number of subjects: 579
Study 30725402 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 853520 200 mg QD
Number of subjects: 21
Study 30725402 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 853520
Number of subjects: 21
Study 30726108 — intervention group
Group type: EXPERIMENTAL
Intervention: Normocytic anemia
Number of subjects: 1789
Study 30726175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (2 mg/kg every 3 weeks for up to 2 years)
Number of subjects: 50
Study 30726184 — intervention group
Group type: EXPERIMENTAL
Intervention: Good collaterals
Number of subjects: 130
Study 30726184 — intervention group
Group type: COMPARATOR
Intervention: Poor collaterals
Number of subjects: 130
Study 30726184 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Number of subjects: 130
Study 30727950 — intervention group
Group type: EXPERIMENTAL
Intervention: Male partners receiving syphilis notification and treatment after partner notification by infected pregnant women.
Number of subjects: 54
Study 30727950 — intervention group
Group type: EXPERIMENTAL
Intervention: Public messaging about syphilis and improved services.
Number of subjects: 54
Study 30728140 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19 CAR T-cell therapy
Number of subjects: 53
Study 30728140 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 53
Study 30728310 — intervention group
Group type: EXPERIMENTAL
Intervention: robot-based therapy targeting finger movements with enhanced proprioceptive feedback for 3 weeks
Number of subjects: 30
Study 30728310 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures related to the somatosensory network
Number of subjects: 30
Study 30728923 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosomal microRNAs 486-5p, 181a-5p and 30d-5p from hypoxic tumour cells
Number of subjects: 0
Study 30729028 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg/day
Number of subjects: 55
Study 30729531 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-directed CAR T-cell therapy
Number of subjects: 92
Study 30729531 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (every 10-year increase)
Number of subjects: 92
Study 30729531 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease type (CLL vs. ALL)
Number of subjects: 92
Study 30729531 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease type (NHL vs. ALL)
Number of subjects: 92
Study 30729531 — intervention group
Group type: EXPERIMENTAL
Intervention: Precollection platelets (every 10 × 10^9/L increase)
Number of subjects: 92
Study 30729531 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte collection efficiency (CE)
Number of subjects: 92
Study 30729729 — intervention group
Group type: COMPARATOR
Intervention: Postural sway measured as AP range during quiet standing with eyes closed on day 3
Number of subjects: 31
Study 30729729 — intervention group
Group type: COMPARATOR
Intervention: Postural sway measured as variability during quiet standing with eyes closed on day 3
Number of subjects: 31
Study 30729729 — intervention group
Group type: COMPARATOR
Intervention: Complexity index of AP COP on day 3
Number of subjects: 31
Study 30729729 — intervention group
Group type: COMPARATOR
Intervention: Complexity index of AP COP on day 21
Number of subjects: 31
Study 30729729 — intervention group
Group type: COMPARATOR
Intervention: Complexity index of AP COP on day 90
Number of subjects: 31
Study 30730031 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye tracking and psychophysiological metrics (using E4 wearable wristband)
Number of subjects: 2
Study 30730031 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimulus task measuring attentional capacity
Number of subjects: 2
Study 30730031 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodermal activity (EDA) measurements
Number of subjects: 2
Study 30730411 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline genetic counseling and multipanel gene testing
Number of subjects: 0
Study 30730411 — intervention group
Group type: EXPERIMENTAL
Intervention: Close prostate specific antigen screening
Number of subjects: 0
Study 30730411 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting PARP enzymes in metastatic, castration resistant prostate cancer
Number of subjects: 0
Study 30730411 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors in cancers with increased tumor mutational burden
Number of subjects: 0
Study 30730782 — intervention group
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (bolus followed by a 2-hour infusion)
Number of subjects: 352
Study 30730923 — intervention group
Group type: EXPERIMENTAL
Intervention: NIH Image J software
Number of subjects: 101
Study 30730923 — intervention group
Group type: COMPARATOR
Intervention: SliceOmatic
Number of subjects: 101
Study 30731276 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 10 mg/kg intravenously every 2 weeks for 12 months
Number of subjects: 62
Study 30731276 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 62
Study 30731280 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical depression in probands
Number of subjects: 837
Study 30731280 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI/overweight in probands
Number of subjects: 837
Study 30732551 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated brain oxygen extraction fraction (OEF) measured by MRI susceptibility in the affected hemisphere (29.3 ± 3.4%)
Number of subjects: 20
Study 30732551 — intervention group
Group type: COMPARATOR
Intervention: Contralateral hemisphere OEF (25.5 ± 3.1%)
Number of subjects: 20
Study 30732640 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-Conformal Radiotherapy (RT) for left-sided BC patients
Number of subjects: 104
Study 30732640 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-Conformal Radiotherapy (RT) for right-sided BC patients
Number of subjects: 104
Study 30732844 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week Mindfulness-Based Attention Training (MBAT)
Number of subjects: 120
Study 30732844 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week Mindfulness-Based Attention Training (MBAT)
Number of subjects: 120
Study 30732844 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Attention Training (MBAT) (both durations)
Number of subjects: 120
Study 30732844 — intervention group
Group type: COMPARATOR
Intervention: No Training Control (NTC)
Number of subjects: 120
Study 30733270 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly carfilzomib at 27 mg/m2
Number of subjects: 0
Study 30733270 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly carfilzomib at 56 mg/m2
Number of subjects: 0
Study 30733683 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year Mediterranean type diet
Number of subjects: 1250
Study 30733874 — intervention group
Group type: EXPERIMENTAL
Intervention: Pigtail probe followed by self-retaining silicone bicanalicular stent insertion for 6 months
Number of subjects: 24
Study 30734042 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy plus standard medical therapy
Number of subjects: 182
Study 30734042 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy alone
Number of subjects: 182
Study 30735141 — intervention group
Group type: EXPERIMENTAL
Intervention: EVIDENT smartphone app
Number of subjects: 362